InflaRx Reports Third Quarter 2021 Financial & Operating Results
November 05, 2021 07:30 ET
|
InflaRx N.V.
Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for Phase III program with vilobelimab in HSIn Phase...
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
November 03, 2021 07:30 ET
|
InflaRx N.V.
JENA, GERMANY, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
October 27, 2021 07:30 ET
|
InflaRx N.V.
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohortTreatment was well tolerated; no dose-related adverse events observedFinal...
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19
October 19, 2021 07:30 ET
|
InflaRx N.V.
Initial portion of the grant amounts to EUR 25.8 millionRemainder of the grant will be awarded in three additional milestone-dependent tranches JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) --...
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
October 12, 2021 07:30 ET
|
InflaRx N.V.
Study has enrolled 369 patients across 9 countriesTopline results expected to be available in Q1 2022 JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage...
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
September 08, 2021 07:30 ET
|
InflaRx N.V.
InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions – including reductions of draining...
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum
August 10, 2021 07:30 ET
|
InflaRx N.V.
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesionTreatment was well tolerated; no adverse events associated with dose...
InflaRx to Present at the BTIG Virtual Biotechnology Conference
August 06, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will...
InflaRx Reports Second Quarter 2021 Financial & Operating Results
August 05, 2021 07:30 ET
|
InflaRx N.V.
Severe COVID-19 trial enrollment reaches 299 patients; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable...